Oberhofer Angela, Bronkhorst Abel J, Uhlig Carsten, Ungerer Vida, Holdenrieder Stefan
Munich Biomarker Research Center, Institute of Laboratory Medicine, German Heart Center, Technical University Munich, Lazarettstraße 36, D-80636 Munich, Germany.
Diagnostics (Basel). 2022 Jul 29;12(8):1834. doi: 10.3390/diagnostics12081834.
All cell and tissue types constantly release DNA fragments into human body fluids by various mechanisms including programmed cell death, accidental cell degradation and active extrusion. Particularly, cell-free DNA (cfDNA) in plasma or serum has been utilized for minimally invasive molecular diagnostics. Disease onset or pathological conditions that lead to increased cell death alter the contribution of different tissues to the total pool of cfDNA. Because cfDNA molecules retain cell-type specific epigenetic features, it is possible to infer tissue-of-origin from epigenetic characteristics. Recent research efforts demonstrated that analysis of, e.g., methylation patterns, nucleosome occupancy, and fragmentomics determined the cell- or tissue-of-origin of individual cfDNA molecules. This novel tissue-of origin-analysis enables to estimate the contributions of different tissues to the total cfDNA pool in body fluids and find tissues with increased cell death (pathologic condition), expanding the portfolio of liquid biopsies towards a wide range of pathologies and early diagnosis. In this review, we summarize the currently available tissue-of-origin approaches and point out the next steps towards clinical implementation.
所有细胞和组织类型都会通过各种机制,包括程序性细胞死亡、意外的细胞降解和主动外排,持续向人体体液中释放DNA片段。特别是,血浆或血清中的游离DNA(cfDNA)已被用于微创分子诊断。导致细胞死亡增加的疾病发作或病理状况会改变不同组织对cfDNA总库的贡献。由于cfDNA分子保留了细胞类型特异性的表观遗传特征,因此有可能从表观遗传特征推断其组织来源。最近的研究表明,例如通过分析甲基化模式、核小体占有率和片段组学,可以确定单个cfDNA分子的细胞或组织来源。这种新颖的组织来源分析能够估计不同组织对体液中总cfDNA库的贡献,并找到细胞死亡增加(病理状况)的组织,从而将液体活检的范围扩展到广泛的病理学和早期诊断。在这篇综述中,我们总结了目前可用的组织来源分析方法,并指出了临床应用的下一步方向。